Moingeon
Phiippe Moingeon, Verrrieres Le Buisson FR
Patent application number | Description | Published |
---|---|---|
20150210742 | NOVEL ALLERGEN FROM RAGWEED POLLEN AND USES THEREOF - The present invention notably concerns a novel major allergen from ragweed pollen, named Amb a X, as well as isoallergens and isoforms thereof. Fragments of the aforementioned polypeptides and homologous polypeptides, in particular homologous polypeptides in related plant species, also make part of the invention. The invention also concerns uses of said polypeptides, in particular for diagnosing and preventing or treating an allergy. | 07-30-2015 |
Philippe Moingeon, Pommiers FR
Patent application number | Description | Published |
---|---|---|
20100260807 | Methods of Inducing and/or Enhancing an Immune Response To Tumor Antigens - An improved method of inducing and/or enhancing an immune response to a tumor antigen is disclosed. The method involves administering the tumor antigen, nucleic acid coding therefor, vectors and/or cells comprising said nucleic acid, or vaccines comprising the aforementioned to a lymphatic site. | 10-14-2010 |
20110250234 | Immunogenic Polypeptides Encoded by MAGE Minigenes and Uses Thereof - The invention discloses immunogenic polypeptides comprising several MAGE-specific antigen epitopes selected from different (i.e. discrete) members of the MAGE protein family, nucleic acids coding therefor, recombinant viruses and/or cells comprising said nucleic acids, and compositions thereof. Methods for eliciting or inducing MAGE-specific immune responses utilizing the aforementioned immunogenic agents are also disclosed. | 10-13-2011 |
20110319480 | Method of Inducing and/or Enhancing an Immune Response to Tumor Antigens - An improved method of inducing and/or enhancing an immune response to a tumor antigen is disclosed. The method involves administering the tumor antigen. nucleic acid coding therefor, vectors and/or cells comprising said nucleic acid or vaccines comprising the aforementioned to a lymphatic site. | 12-29-2011 |
20130216563 | Immunogenic Polypeptides Encoded by MAGE Minigenes and Uses Thereof - The invention discloses immunogenic polypeptides comprising several MAGE-specific antigen epitopes selected from different (i.e. discrete) members of the MAGE protein family, nucleic acids coding therefor, recombinant viruses and/or cells comprising said nucleic acids, and compositions thereof. Methods for eliciting or inducing MAGE-specific immune responses utilizing the aforementioned immunogenic agents are also disclosed. | 08-22-2013 |
Philippe Moingeon, Antony FR
Patent application number | Description | Published |
---|---|---|
20080233155 | Compositions For Antigen-Specific Induction of Tolerance - The invention relates to an immunogenic composition for sublingual, perlingual or oral administration, comprising at least an antigen and at least an adjuvant that is a bacterium selected from a Bifidobacterium and a lactic acid bacterium, and/or a combination of a corticosteroid with vitamin D3 or any metabolite or analog of the latter, in a pharmaceutically acceptable carrier that is suitable for sublingual, perlingual, or oral administration. Such compositions allow to elicit antigen-specific immune tolerance. | 09-25-2008 |
20080274059 | MITE FUSION PROTEINS - The present invention relates to fusion proteins comprising a Group I allergen and a Group II allergen from the genus | 11-06-2008 |
20110150987 | MUCOADHESIVE PARTICULATE FORMULATION FOR INDUCING ANTIGEN-SPECIFIC IMMUNE TOLERANCE - The present invention relates to a mucoadhesive composition, adapted for preventing and/or treating a pathological reaction of the immune system of an individual, by inducing a specific tolerance towards at least one antigen involved in said pathological reaction, comprising chitosan particles loaded with said at least one antigen involved in the pathological reaction, wherein the size of the loaded chitosan particles is of more than 800 nm. | 06-23-2011 |
20140079795 | MUCOADHESIVE PARTICULATE FORMULATION FOR INDUCING ANTIGEN-SPECIFIC IMMUNE TOLERANCE - The present disclosure relates to a mucoadhesive composition, adapted for preventing and/or treating a pathological reaction of the immune system of an individual, by inducing a specific tolerance towards at least one antigen involved in said pathological reaction, comprising chitosan particles loaded with said at least one antigen involved in the pathological reaction, wherein the size of the loaded chitosan particles is of more than 800 nm. | 03-20-2014 |
Philippe Moingeon, Verrieres Le Buisson FR
Patent application number | Description | Published |
---|---|---|
20110293665 | Recombinant Der P 2 Expressed in Pichia Pastoris as a "Natural-Like" Allergen for Immunotherapy and Diagnostic Purposes - The present invention concerns a method for producing a recombinant | 12-01-2011 |
20120148626 | REDUCTION OF IN VITRO GENOTOXICITY OF POLLEN EXTRACTS BY REMOVAL OF FLAVONOIDS - The invention relates to grass pollen extracts containing reduced amount of flavonoid glycosides in order to minimize the risks of genotoxicity of the grass pollen extracts. The invention also relates to a method of preparing grass pollen extracts containing reduced amount of flavonoid glycosides by ultrafiltration. Flavonoid glycosides are naturally present in grass pollen extracts and they have been identified as being responsible for the formation of flavonoid aglycones, which are genotoxic in vitro, under the influence of enzymes contained in the grass pollen extracts. | 06-14-2012 |
20120171198 | USE OF IGG1 IMMUNOGLOBULINS AND/OR LIGANDS OF THE CD32 RECEPTOR FOR TREATING INFLAMMATORY DISEASES AND MANIFESTATIONS VIA THE MUCOSAL ROUTE - The present invention concerns the use of immunoglobulins of IgG | 07-05-2012 |
20120171710 | Method for Grass Species Identification - The present invention relates to the use of at least one peptide comprising or consisting of a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, for determining the presence of extracts from at least one grass species in a composition. | 07-05-2012 |
20140112955 | BIOMARKERS OF IMMUNOTHERAPY EFFICACY - The invention relates to proteins for use as a marker for the efficacy of sublingual immunotherapy. In particular, the proteins may be used to predict the responsiveness of a patient to immunotherapy. The invention may find use in selecting patients as suitable candidates for immunotherapy. | 04-24-2014 |
Philippe Moingeon, Verrieres-Ie-Buisson FR
Patent application number | Description | Published |
---|---|---|
20140377761 | METHODS FOR IDENTIFYING DENDRITIC CELL SUBSETS, FOR DETERMINING IF A PATIENT IS DEVELOPING A REGULATORY OR AN EFFECTOR IMMUNE RESPONSE, AND FOR DETERMINING RESPONSE TO IMMUNOTHERAPY - The present invention concerns methods for determining if a dendritic cell belongs to a tolerogenic dendritic cell subset or to an effector dendritic cell subset, and methods for determining if a patient undergoing immunotherapy, and/or who has been administered with a vaccine, is developing an immune response oriented either towards a regulatory T cell response or towards an effector T cell response, and methods of determining response to immunotherapy. | 12-25-2014 |
Phillipe Moingeon, Pommiers FR
Patent application number | Description | Published |
---|---|---|
20150352198 | Method of Inducing And/Or Enhancing An Immune Response to Tumor Antigens - An improved method of inducing and/or enhancing an immune response to a tumor antigen is disclosed. The method involves administering the tumor antigen, nucleic acid coding therefor, vectors and/or cells comprising said nucleic acid, or vaccines comprising the aforementioned to a lymphatic site. | 12-10-2015 |